Type 1 diabetes stem cell gene therapy (Altheia Science)

N/A

Report date: 2025/05/09 10:39:03

Base Information

Drug NameType 1 diabetes stem cell gene therapy (Altheia Science)

Drug Alias NameAutologous Hematopoietic Stem and Progenitor Cells (HSPCs)

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionStem cell replacementsProgrammed death-ligand 1 agonists

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsDiabetes Mellitus, Type 1

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAltheia Science Srl

China Registration ClassN/A

Develop Information

Active CompaniesAltheia Science Srl

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 1

Inactive IndicationsN/A

Other Information

ATC CodeN/A